about
Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issuesGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Measuring health: a practical challenge with a philosophical solution?Cost-effectiveness of primary offer of IVF vs. primary offer of IUI followed by IVF (for IUI failures) in couples with unexplained or mild male factor subfertility.Informal knowledge transfer in the period before formal health education programmes: case studies of mass media coverage of HIV and SIDS in England and Wales.Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK populationPolygenic susceptibility to prostate and breast cancer: implications for personalised screeningRoutine urinalysis of patients in hospital in Lebanon: how worthwhile is it?A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK.Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.Survival trends for small intestinal cancer in England and Wales, 1971-1990: national population-based study.Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East AngliaIncidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing.Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges.Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulationComparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.Blood lipids and prostate cancer: a Mendelian randomization analysis.Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.Stage shift in PSA-detected prostate cancers - effect modification by Gleason score.Mortality attributable to excess adiposity in England and Wales in 2003 and 2015: explorations with a spreadsheet implementation of the Comparative Risk Assessment methodology.Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study.Cervical cancer in Indigenous women: The case of Australia.Preconception healthcare and congenital disorders: systematic review of the effectiveness of preconception care programs in the prevention of congenital disorders.Preconception healthcare delivery at a population level: construction of public health models of preconception care.SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns.Evaluation of recruitment and selection for specialty training in public health: interim results of a prospective cohort study to measure the predictive validity of the selection process.Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.Genome-wide association study of prostate cancer-specific survival.Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.What ethical and legal principles should guide the genotyping of children as part of a personalised screening programme for common cancer?Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium.Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis.
P50
Q26825771-2BF5A1F9-189B-41EF-89B5-CEF6FA68ACFFQ28388497-2DD8EB0D-0314-4F00-8AA8-3E9825949458Q29417155-B9F8E58A-D989-4883-AB3B-5365F045F52CQ30398379-AC00BD75-E04D-4B22-A73F-22A82C025EC1Q33247781-7066BF7C-7C9F-42CE-87CC-1EE0F7A59E0EQ33302966-54524988-9A37-4322-BEE6-92E80A203CCBQ33483126-C2EBFE39-92DC-4AB0-953F-70256931C62CQ34977428-5EAD28B5-6052-448F-BF3D-BD5959E65BC1Q35041184-B8E621C2-AAC9-402E-AF5B-2F57E8C1F223Q35248192-C10ADAF6-D740-446A-B915-B6BE8BDD7F08Q35592936-DBD77F66-E17F-4ECD-9034-45B561738639Q35602297-91E908D8-DE5F-4FB1-B0C8-765AD40971E3Q35646703-C8030431-F05F-4515-A38B-624B61F7963EQ35815958-0CC41B97-9688-4D39-9A4C-7916C2ABB2E5Q36133295-E790D353-DD3F-4534-9A7A-4493587E70AAQ36295073-38231859-325F-49C3-BB57-1F5232EBA17AQ36611833-1B61F7F1-7138-4F82-88C1-58FCCF41C017Q36612163-3D66DD48-E5C0-4B5D-9805-567DC50AFA80Q36612179-2945BA68-FF20-4A5D-9D23-81C266552ED8Q36763159-B85BF544-44AF-4EC7-8A03-6974019E03A4Q36765569-1F655C54-D4E4-44DB-B79D-FE9DB6F63F73Q36792641-B50178C0-CF10-4FF4-B502-60BD5E1B3A8EQ36793558-28278FA6-6B42-435D-B696-A11C3C42790CQ37045556-860DD92D-2E1B-493C-B822-5C2EA71771D6Q37118791-54D5919E-9E38-46EF-BC19-E12E0D6684B9Q37160706-C53E2064-B5A8-4531-8B0E-786030DE751BQ37248410-B7FB599A-6694-4CD2-A40C-18A2951688C7Q37270655-3DC01F13-B118-4EB7-A940-94EDDC9C9369Q37417691-40C1D81E-B8B5-4EF4-9D94-7A0B879344D5Q37926139-39862D43-D6BD-4640-A4D6-A65A4218673EQ38148992-11CE4C8E-E0DC-4C28-9BFF-D4E0473E21CCQ38162778-846B770E-713B-477C-AF9A-DCE22060CE63Q38382935-99A43368-4153-48EE-ACF8-93A905F93B90Q38565081-FAD24021-A3CD-4450-857E-5A11A11F6FE1Q38647896-5DA8EC3F-DCC5-42EA-A16E-5B529CDB3DCEQ38970751-8C6686D2-1836-415D-98F6-0041C19E8DC8Q39182862-43D5FBA8-725E-423F-BEA1-49EAC6F9D809Q39458551-A7BA4DEA-D0B6-4AFC-8C7A-2179E3945217Q39524941-5E8ACF9F-4334-4D45-AB10-3CF55AB11815Q40515571-2F7C9662-CF2F-4790-B5DA-CF95E2CC5C7A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nora Pashayan
@ast
Nora Pashayan
@en
Nora Pashayan
@es
Nora Pashayan
@nl
Nora Pashayan
@sl
type
label
Nora Pashayan
@ast
Nora Pashayan
@en
Nora Pashayan
@es
Nora Pashayan
@nl
Nora Pashayan
@sl
altLabel
Pashayan N
@en
prefLabel
Nora Pashayan
@ast
Nora Pashayan
@en
Nora Pashayan
@es
Nora Pashayan
@nl
Nora Pashayan
@sl
P106
P1153
14060827200
P21
P31
P496
0000-0003-0843-2468